Connect your AI

Immunome IMNM Operating lease liabilities

Operating lease liabilities at other companies

SELLAS Life Sciences Group, Inc.SLS

——

ArriVent BioPharma, Inc.AVBP

——

Crinetics PharmaceuticalsCRNX

——

ModernaMRNA

——

Other financials

Income statement

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Immunome's operating lease liabilities?: Immunome (IMNM) reported operating lease liabilities of -$161K in Q1 2026.
How has Immunome's operating lease liabilities changed year-over-year?: Immunome's operating lease liabilities decreased by 159.7% year-over-year, from -$62K to -$161K.